Experimental therapeutics of neurodegenerative disorders: unmet needs.
Viewpoint The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery-such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders.
Shoulson
I
I
Department of Neurology, University of Rochester Medical Center, School of Medicine and Dentistry, Suite 212, 1351 Mt. Hope Avenue, Rochester, NY 14620, USA.
D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D001812:Blood-Brain Barrier; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D020022:Genetic Predisposition to Disease; D006527:Hepatolenticular Degeneration / Q000188:drug therapy; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy
D018696:Neuroprotective Agents